SCHEMBL21272263

SCHEMBL21272263

CCCC1=NCC(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.55
▸ NTSR1 P30989 1/20 0.55
▸ OPRK1 P41145 1/20 0.55
▸ PDE4D Q08499 1/20 0.55
▸ GABRA1 P14867 5/20 0.54
▸ GABRA5 P31644 5/20 0.54
▸ GABRA3 P34903 5/20 0.54
▸ GABRA2 P47869 5/20 0.54
▸ GABRB2 P47870 5/20 0.54
▸ GABRG2 P18507 4/20 0.54
▸ GABRB3 P28472 4/20 0.54
▸ GABRP O00591 3/20 0.54
▸ GABRD O14764 3/20 0.54
▸ GABRB1 P18505 3/20 0.54
▸ GABRA4 P48169 3/20 0.54
▸ GABRE P78334 3/20 0.54
▸ GABRA6 Q16445 3/20 0.54
▸ GABRG1 Q8N1C3 3/20 0.54
▸ GABRG3 Q99928 3/20 0.54
▸ GABRQ Q9UN88 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21272173 0.84 CHRM1 (0.55) CNR1NTSR1OPRK1PDE4DGABRA1
SCHEMBL11827239 0.81 PGR (0.67) CNR1NTSR1OPRK1PDE4DGABRA1
SCHEMBL1515097 0.78 CNR1 (0.65) CNR1NTSR1OPRK1PDE4DGABRA1
Nordazepam SCHEMBL29354494 0.71 PDE4D (1.00) CNR1NTSR1OPRK1PDE4DGABRA1
Nordazepam SCHEMBL78453 0.71 PDE4D (1.00) CNR1NTSR1OPRK1PDE4DGABRA1
Nordazepam SCHEMBL8090999 0.71 PDE4D (1.00) CNR1NTSR1OPRK1PDE4DGABRA1
Nordazepam SCHEMBL31000330 0.71 PDE4D (1.00) CNR1NTSR1OPRK1PDE4DGABRA1
SCHEMBL2364518 0.71 GABRA1 (0.54) CNR1NTSR1OPRK1PDE4DGABRA1
SCHEMBL9519475 0.71 KMT2A (0.67) CNR1NTSR1OPRK1PDE4DGABRA1
Delorazepam SCHEMBL32681132 0.70 GABRA1 (1.00) CNR1NTSR1OPRK1PDE4DGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021448-B2 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases HOFFMANN-LA ROCHE INC. (US) 2021-06-01 — — US disclosed
EP-3535253-A1 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES H. Hoffnabb-La Roche Ag (CH) 2019-09-11 — — EP disclosed
US-20190256478-A1 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES HOFFMANN-LA ROCHE INC. (US) 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11021448-B2 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases CHRM1, CHRM2, CHRM4 CNR1 6/4885NTSR1 666/4885OPRK1 19/4885
US-20190256478-A1 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES CHRM1, CHRM2, CHRM4 CNR1 6/4885NTSR1 666/4885OPRK1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback